title: Effects of olanzapine-fluoxetine combination treatment of major depressive disorders on the quality of life during acute treatment period.
abstract: The objective of the study was to explore the effects of olanzapine-fluoxetine combination (OFC) treatment of major depressive disorders on the quality of life in the acute treatment period. Methods were prospective and observational design. One hundred and three patients of major depressive disorders were observed. One group of 53 patients received OFC treatment (OFC group); the other group of 50 patients received the treatment of duloxetine (duloxetine group). Two groups were needed to be observed 8 weeks. Observed indicators were Hamilton Depression Rating Scale for Depression (HAMD-24) and four factor scores: the slow, sleep disorders, anxiety/somatization, and hopelessness, Clinical Global Impression-Severity of Illness (CGI-S), WHO quality of life scale (WHOQOL-BREF), and sub-rate measurements. HAMD-24 and four factor scores observation time were assessed before and after treatment; 1, 2, 4, 8 weeks, WHOQOL-BREF score, and sub-time measurements were assessed before treatment and 8 weeks after treatment. HAMD-24 scores of OFC patients in the first week were significantly lower than those of the duloxetine group. The sleep factor scores of OFC patients were significantly lower than those of the duloxetine group in 4 and 8 weeks. By the end of 8 weeks, OFC group was rated significantly lower than the duloxetine group in the physical area. In the acute treatment period, OFC treatment effected faster than the single duloxetine in patients with major depressive disorders. OFC effected within 1 week and was better than the single duloxetine in improving the sleep and physical conditions.
authors: Clinical Psychology Department, Southwest Hospital, Chongqing, 400038, China, Quwei6377@aliyun.com.
authors: Wei
authors: W
authors: Qu
authors: Shanshan
authors: S
authors: Gu
authors: Han
authors: H
authors: Luo
authors: Qianying
authors: Q
authors: Tang
authors: Junwei
authors: J
authors: Guo
mesh_terms: D000328:Adult; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004334:Drug Administration Schedule; D004338:Drug Combinations; D000068736:Duloxetine Hydrochloride; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D011788:Quality of Life; D012893:Sleep Wake Disorders / Q000209:etiology; D013001:Somatoform Disorders / Q000209:etiology; D013876:Thiophenes / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D004338:Drug Combinations; D013876:Thiophenes; C492572:olanzapine-fluoxetine combination; D005473:Fluoxetine; D001569:Benzodiazepines; D000068736:Duloxetine Hydrochloride